Avanza Fonder Ab Merus N.V. Transaction History
Avanza Fonder Ab
- $3.38 Trillion
- Q2 2025
A detailed history of Avanza Fonder Ab transactions in Merus N.V. stock. As of the latest transaction made, Avanza Fonder Ab holds 3,136 shares of MRUS stock, worth $192,675. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,136
Previous 2,749
14.08%
Holding current value
$192,675
Previous $118 Million
39.51%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding MRUS
# of Institutions
195Shares Held
62.3MCall Options Held
355KPut Options Held
96.5K-
Wellington Management Group LLP Boston, MA4.72MShares$290 Million0.04% of portfolio
-
Commodore Capital LP New York, NY4.47MShares$275 Million18.43% of portfolio
-
Rtw Investments, LP New York, NY4.17MShares$256 Million2.88% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY3.37MShares$207 Million7.27% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.17MShares$195 Million3.38% of portfolio
About Merus N.V.
- Ticker MRUS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,878,200
- Market Cap $2.82B
- Description
- Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...